Lambda–Kappa Light Chain Pairing to Reduce Antibody Shuffling

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Mispairing of light chains, known as light chain shuffling, frequently occurs during the production of bispecific and other multispecific antibodies, leading to decreased production yield and incorrect antibody pairings.

Innovation Solution

A method of expressing four non-contiguous polypeptides in a cell, including a first and second heavy chain polypeptides and lambda and kappa light chain polypeptides, where the affinities between these polypeptides are specifically engineered to minimize light chain shuffling, allowing for higher yields of stable multispecific molecules.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional methods are used to produce bispecific antibodies, then light chain shuffling occurs frequently, but production yield decreases

Engineering Contradiction:
Improveproduction yieldVSAvoidlight chain pairing accuracy
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent divides the antibody production system into separate expression components, expressing heavy chains and light chains in separate vectors with controlled co-expression. This segmentation allows independent optimization of each component's expression and facilitates precise control over pairing outcomes, reducing light chain shuffling while maintaining high production yield

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent introduces a controlled cellular environment as an intermediary system that manages the interaction between heavy and light chains. By using specific cell lines and controlled co-expression conditions, the system acts as a mediator that directs correct pairing while minimizing incorrect pairings, thus resolving the contradiction between yield and pairing accuracy

Inventive Principle:
Principle #24Intermediary (Mediator)

2Productivity

If light chain shuffling is frequent, then incorrect antibody pairings are formed, but production efficiency decreases

Engineering Contradiction:
Improveproduction efficiencyVSAvoidantibody pairing specificity
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent employs preliminary action by pre-designing the expression system with specific promoters, vectors, and cellular conditions that favor correct pairing before the actual antibody assembly occurs. This preliminary setup ensures that when heavy and light chains interact, the correct pairings are formed with high efficiency, avoiding incorrect pairings and maintaining both productivity and precision

Inventive Principle:
Principle #10Preliminary action

3Productivity

If affinity between light chains and heavy chains is not specifically engineered, then light chain shuffling occurs, but with engineered affinities production yield increases significantly

Engineering Contradiction:
Improveproduction yieldVSAvoidaffinity engineering complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by systematically adjusting affinity parameters between light chains and heavy chains through controlled mutagenesis and selection. By optimizing specific amino acid residues at the interface, the system achieves high production yield with engineered affinities, managing the complexity through focused parameter optimization rather than complete redesign

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method results in a significant increase in the production of multispecific molecules, with yields at least 5.25-fold higher than traditional methods, while maintaining the stability and specificity of the antibody pairings.

Implementation Method 1

the affinities between these polypeptides are specifically engineered to minimize light chain shuffling

Methodology Applied
Scientific EffectProtein-protein binding affinity:

Data Source

PatentUS12421323B2Multispecific antibody molecules comprising lambda and kappa light chains
Publication Date: 2025.09.23 MARENGO THERAPEUTICS INC
  • US12421323B2 patent drawing
  • US12421323B2 patent drawing
  • US12421323B2 patent drawing

AI summary

Multispecific, e.g., bispecific, antibody molecules that include a kappa light chain polypeptide and one lambda light chain polypeptide, and methods of making and using the multispecific antibody molecules, are disclosed.